Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes

Bone Marrow Transplantation

Volumn 35, Issue 10, 2005, Pages 965-970

  Kebriaei, P ^a   Kline, J ^a   Stock, W ^a   Kasza, K ^a   Le Beau, M M ^a   Larson, R A ^a   van Besien, K ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Prognosis

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; HLA ANTIGEN; MELPHALAN; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER CLASSIFICATION; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELL COUNT; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DONOR; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK FACTOR; SCORING SYSTEM; SIBLING; TIME; TREATMENT OUTCOME; UNITED STATES; WHOLE BODY RADIATION;

ADULT; AGED; COST OF ILLNESS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 19044388157     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704938     Document Type: Article

References (30)

1. Champlin R, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood 1987; 69: 1551-1562.
2. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
3. Sierra J, Storer B, Hansen JA et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397-404.
4. Burnett AK, Goldstone AH, Stevens RF et al. The Role of BMT in Addition to Intensive Chemotherapy in AML in First CR: Results of the MRC AML-10 Trial. San Diego, CA: American Society of Hematology, 1994, p 252a.
5. Ferrant A, Doyen C, Delannoy A et al. Karyotype in acute myeloblastic leukemia: prognostic significance in a prospective study assessing bone marrow transplantation in first remission. Bone Marrow Transplant 1995; 15: 685-690.
6. Ferrant A, Labopin M, Frassoni F et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90: 2931-2938.
7. Gale RP, Horowitz MM, Weiner RS et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995; 16: 203-208.
8. Greinix HT, Nachbaur D, Krieger O et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol 2002; 117: 914-923.
9. Byrd JC, Mrozek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
10. Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
11. Visani G, Bernasconi P, Boni M et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia - analysis of 848 patients. Leukemia 2001; 15: 903-909.
12. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
13. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
14. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
15. Kaplan E. Nonparametric estimation for incomplete observations. J Am Statist Assoc 1958; 53: 457-481.
16. Cox D. Regression models and life tables. J Roy Statist Soc B 1972; 34: 187-220.
17. van Besien K, Smith S, Detenike O et al. Alemtuzumab (Campath) based GVHD Prophylaxis Leads to Improved Survival after Allogeneic Transplantation for Patients with Advanced Hematologic Malignancies. San Diego, CA: American Society of Hematology, 2003.
18. Clift RA, Buckner CD, Thomas ED et al. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243-258.
19. Cliff RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10: 1723-1729.
20. Appelbaum FR, Clift RA, Buckner CD et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood 1983; 61: 949-953.
21. Horowitz MM, Rowlings PA. An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol 1997; 4: 395-400.
22. Venditti A, Maurillo L, Buccisano F et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 2003; 17: 2178-2182.
23. Wolfgang Kern MS, Schmid C, Schoch C et al. Allogeneic Stem Cell Transplantation Immediately After Cytoreductive Chemotherapy or After Achievement of Complete Remission in Patients with Refractory and Relapsed Acute Myeloid Leukemia: Cytogenetically Stratified Matched-Pair Analysis of 125 Patients. Session Type: Oral Session. San Diego, CA: American Society of Hematology, 2003.
24. Markus Andreas Schaich MF, Bornhaeuser M, Thiede C et al. Rapid Risk-Profiling Including Fast Donor Search within a Multi-Center Trial Allows for Early Allogeneic Stem Cell Transplantation during Aplasia in Patients with High-Risk Acute Myeloid Leukemia. San Diego, CA: American Society of Hematology, 2004.
25. Venditti A, Buccisano F, Del Poeta G et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948-3952.
26. Venditti A, Maurillo L, Buccisano F et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 2003; 17: 2178-2182.
27. Copelan EA, Penza SL, Elder PJ et al. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplant 2000; 25: 1219-1222.
28. Frassoni F, Labopin M, Powles R et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 2000; 355: 1393-1398.
29. Daniel A, Pollyea ASA, Stock W et al. Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST). San Diego, CA: American Society of Hematology, 2004.
30. Mohamed Sorror MM, Baron F, Sandmaier B et al. A Modified Hematopoietic Cell Transplantation (HCT)-Specific-Comorbidity Index. San Diego, CA: American Society of Hematology, 2004.